Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience.
Stoetzer O, Di Gioia D, Issels RD, Abdel-Rahman S, Mansmann U, Lindner LH, Gluz O, Würstlein R, Braun M, Hamann M, Edler von Koch F, Harbeck N, Salat C. Stoetzer O, et al. Breast Care (Basel). 2021 Apr;16(2):173-180. doi: 10.1159/000507473. Epub 2020 May 12. Breast Care (Basel). 2021. PMID: 34012372 Free PMC article.
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial.
von Einem JC, Peter S, Günther C, Volk HD, Grütz G, Salat C, Stoetzer O, Nelson PJ, Michl M, Modest DP, Holch JW, Angele M, Bruns C, Niess H, Heinemann V. von Einem JC, et al. Among authors: stoetzer o. Oncotarget. 2017 Sep 16;8(46):80156-80166. doi: 10.18632/oncotarget.20964. eCollection 2017 Oct 6. Oncotarget. 2017. PMID: 29113291 Free PMC article.
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT-ME-1 trial.
von Einem JC, Guenther C, Volk HD, Grütz G, Hirsch D, Salat C, Stoetzer O, Nelson PJ, Michl M, Modest DP, Holch JW, Angele M, Bruns C, Niess H, Heinemann V. von Einem JC, et al. Among authors: stoetzer o. Int J Cancer. 2019 Sep 15;145(6):1538-1546. doi: 10.1002/ijc.32230. Epub 2019 Mar 13. Int J Cancer. 2019. PMID: 30801698 Clinical Trial.
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.
Wuerstlein R, Harbeck N, Grischke EM, Forstmeyer D, von Schumann R, Krabisch P, Lüdtke-Heckenkamp K, Stefek A, Stoetzer O, Grafe A, Kaltenecker G, Forstbauer H, Augustin D, Schrader I, Tio J, Nitz U, Gluz O, Kates RE, Graeser MK. Wuerstlein R, et al. Among authors: stoetzer o. Breast Care (Basel). 2021 Feb;16(1):50-58. doi: 10.1159/000506622. Epub 2020 Apr 6. Breast Care (Basel). 2021. PMID: 33716632 Free PMC article.
Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.
Braun M, Kriegmair A, Szeterlak N, Andrulat A, Schrodi S, Kriner M, Hanusch C, Hamann M, Stoetzer O, Pölcher M. Braun M, et al. Among authors: stoetzer o. Breast Care (Basel). 2022 Jun;17(3):288-295. doi: 10.1159/000521096. Epub 2021 Nov 26. Breast Care (Basel). 2022. PMID: 35957951 Free PMC article.
32 results